The effect of hypoalbuminemia is most pronounced in patients receiving first cycle MWA and remains an indicator of progression risk in optimal bridge to LT candidates with well-preserved liver function, limited HCC burden, and low AFP levels. The gene discussed is AFP; the disease is Hypoalbuminemia.